University of Washington spinout AltPep, which is developing tests and treatments for Alzheimer’s and Parkinson’s disease, completed a $52.9 million Series B funding round.
The funding will help propel the company’s experimental treatments into clinical trials and support its regulatory application for a blood test to detect Alzheimer’s disease at its earliest stages, according to a statement Thursday announcing the funding.
